Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has launched Cefotan® (cefotetan for injection). This is the Company's first product launched from the portfolio of discontinued and withdrawn new drug applications (NDAs) and abbreviated new drug applications (ANDAs), which the Company purchased from AstraZeneca on September 25, 2014.